AEON Biopharma reports Q1 cash $6.2M; FDA supports ABP-450 biosimilar plan; debt cut >90%

AEON Biopharma, Inc.

FDA BPD Type 2a meeting deemed AEON's analytical similarity strategy reasonable for 351(k) pathway.
Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by >90%.
Appointed John Bencich as CFO, bringing 25+ years of corporate and capital markets experience.
Cash and cash equivalents $6.2M at March 31, plus $0.9M April ATM; funds operations into Q3 2026.
Plans BPD Type 2b meeting in H2 2026 to discuss remaining biosimilar development program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the first quarter ended March 31, 2026.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-26-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.